Alterity Therapeutics (ATH) Q3 2026 TU earnings summary

Executive summary

• Achieved alignment with the FDA on key elements of the planned Phase 3 program for ATH434 in Multiple System Atrophy (MSA), with End-of-Phase 2 meeting on track for mid-2026.

• Presented new Phase 2 data at the American Academy of Neurology, showing consistent efficacy of ATH434 in slowing disease progression in MSA.

• Strengthened leadership with the appointment of Dr. Daniel Claassen as Chief Medical Advisor and Ms. Ann Cunningham as Non-Executive Director.

• Engaged in ongoing strategic collaboration discussions with pharmaceutical companies for ATH434.

Financial highlights

• Cash and cash equivalents of A$44.53 million as of 31 March 2026.

• Operating cash outflows for the quarter were A$4.73 million.

• Net cash from financing activities for the quarter was A$19.17 million.

• Estimated 9.4 quarters of funding available based on current cash burn.

Outlook and guidance

• On track for End-of-Phase 2 FDA meeting for ATH434 in mid-2026, supporting readiness for Phase 3 pivotal trial.

• Strong cash position expected to support regulatory, clinical, and commercial objectives.